Per Chosun Ilbo, the drug missed its Phase 3 goals, and the news drove a steep drop in the company's stock.

Phase 3 is the final gate before approval, and failure there badly disrupts commercialization plans, unwinding investor hopes at once.

The firm, grown fast on obesity and diabetes drugs, had invested in cardiovascular work to diversify; the result underscores the uncertainty of drug development.

Clinical failures are common in pharma, but shocks amplify when market hopes are already priced into shares.

The Bridge Times reports individual share moves without categorical forecasts, alongside the structural uncertainty of drug development.